A new clinical study found that adults who took FOCUSfactor as directed improved their memory, concentration, and focus. FOCUSfactor is a nutritional supplement formulated with a patent-pending blend of brain supporting vitamins, minerals, antioxidants and other nutrients. The clinical study was presented at The Gerontological Society of America’s 64^th Annual Scientific Meeting in late November. With 5400 members from over 40 countries, The Gerontological Society of America is the nation’s oldest and largest interdisciplinary organizations devoted to research, education and practice in the field of aging. 
 
Dr. Gary Kay, a clinical neuropsychologist and President of Cognitive Research Corporation said, “We conducted a randomized, double-blind, placebo-controlled, parallel group study to evaluate the effects of FOCUSfactor on memory, concentration and focus in healthy adults. The results are scientifically and clinically significant.”
 
The clinical study used the Rey Auditory Verbal Learning Test (RAVLT), a standardized, widely used neuropsychological test and one of the most commonly used tests of memory in psychopharmacology research. The RAVLT was originally developed in the 1940s and has proven useful in evaluating verbal learning and memory. The study also used CogScreen, a computer-administered neuropsychological test battery developed for the Federal Aviation Administration for evaluating the cognitive functioning of pilots. The test is used worldwide in pilot selection as well as by the United States military and in clinical research trials evaluating effects of treatments on cognitive functioning. 
 
“The clinical study demonstrated that, compared to placebo, FOCUSfactor improved abilities referred to as memory, concentration, and focus in healthy adults,” said Dr. Kay. “The most dramatic effects were seen on the initial learning trials of RAVLT and were confirmed by findings on the CogScreen measures of concentration and working memory. Following six weeks of treatment, subjects who received FOCUSfactor had a mean increase in recall of 6.5 words compared to 4.5 words for those who received placebo.
 
To better understand the magnitude of the improvement seen with FOCUSfactor, the changes in RAVLT performance seen in this trial can be viewed in terms of the effects that normal aging has on RAVLT performance. The average recall score for the five learning trials of RAVLT for subjects receiving FOCUSfactor is a score that is comparable to the published score obtained by individuals in the 20-29 year age group. In contrast, the average score obtained for subjects who received placebo is comparable to the published score obtained by individuals in the 30-39 year age group.
 
This difference in memory test performance can be considered to reflect a 10-year cognitive age advantage. This is further supported by analysis of the CogScreen results, which show significant improvement with FOCUSfactor compared to placebo on a validated measure of concentration and working memory. In addition to these efficacy findings, the study results demonstrate that FOCUSfactor was very well tolerated by subjects in the study.”
 
There were 96 subjects enrolled in the study between the ages of 18 and 65. The mean age of subjects who participated was 49 years. There were no demographic differences between subjects randomized to FOCUSfactor and those randomized to Placebo. The study was conducted over a six-week period. Eighty-nine subjects completed the six-week study and were included in the data analyses.
 
The clinical study of FOCUSfactor was sponsored by Factor Nutrition Labs and was conducted by Cognitive Research Corporation, a full-service contract research organization that is a leader in analyzing the effects of nutritional supplements, medications, and foods on human cognition and driving. The study was conducted in compliance with all applicable country requirements for the conduct of clinical studies, including those outlined by the International Conference on Harmonization, Consolidated Guidelines on Good Clinical Practices, and the Food and Drug Administration.